Research Article

Insilico investigation of TNFSF10 signaling cascade in ovarian serous cystadenocarcinoma

Asima Tayyeb* and Zafar Abbas Shah

Published: 02 July, 2019 | Volume 3 - Issue 1 | Pages: 025-034

The ovarian serous Cystadenocarcinoma shared large number of deaths in gynecologic carcinoma. It has various numbers of molecular events from initiation to progression and at advance stage, surgery is the end product of such molecular signaling. We assess in this study the whole mechanistic view of TNFSF10 network which has the ideal apoptotic causing identity. We used fresh insilico strategy to uncover the secrets and inter-links from its protein-protein interaction complex. We retrieved the TNFSF10 signaling network from STRING database (www.string-db.org). The network contains 25 nodes and 152 edges with clustering presentation. After retrieval, we performed gene enrichment and characterization analysis of network from WebGestalt toolkit (www.webgestalt.com). Finally, we examined the participation of whole network in ovarian cancer progression from cBioPortal, a cancer genomic data portal (www.cbioportal.org). Our results showed that majority of cases have loss of function of death receptors (DR4 and DR5) that are the main unit of initiation of apoptotic signaling. Most of downstream signaling members showed amplification that regulates cell proliferative pathways including NFkB pathway. TNFSF10 cluster has loss of function and in future it gain attention for further research studies to discover its interactome level view for valuable therapy. FAS cluster has large number of members and majority showed amplification rendering them as co-targets for combinational drug designing.

Read Full Article HTML DOI: 10.29328/journal.acst.1001005 Cite this Article Read Full Article PDF


Ovarian cancer; TNFSF10; TNFSF10; FAS


  1. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, et al. Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem. 1996; 271:12687-12690. Ref.: http://bit.ly/2Nso1Su
  2. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995; 3: 673-682. Ref.: http://bit.ly/2LxPDmv
  3. Kimberley FC, Screaton GR. Following a TRAIL: update on a ligand and its five receptors. Cell Res. 2004; 14: 359. Ref.: http://bit.ly/327eofe
  4. Diehl GE, Yue HH, Hsieh K, Kuang AA, Ho M, et al. TRAIL-R as a negative regulator of innate immune cell responses. Immunity. 2004; 21: 877-889. Ref.: http://bit.ly/2LulNzj
  5. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, et al. Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice. J Immunol. 2002; 168: 1356-1361. Ref.: http://bit.ly/2xnjPZf
  6. Abdulghani J, El-Deiry WS. TRAIL receptor signaling and therapeutics. Expert Opin Ther Targets. 2010; 14: 1091-1108. Ref.: http://bit.ly/2JpayFw
  7. Wang X. The expanding role of mitochondria in apoptosis. Genes Dev. 2001; 15: 2922-2933. Ref.: http://bit.ly/2FM402U
  8. Lin Y, Devin A, Cook A, Keane MM, Kelliher M, et al. The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IκB kinase and c-Jun N-terminal kinase. Mol Cell Biol. 2000; 20: 6638-6645. Ref.: http://bit.ly/2XFqZH3
  9. Wajant H. TRAIL and NFκB signaling—a complex relationship. Vitamins & Hormones. 2004; 67: 101-132. Ref.: http://bit.ly/2YptNoF
  10. Wajant H, Gerspach J, Pfizenmaier K. Tumor therapeutics by design: targeting and activation of death receptors. Cytokine & growth factor reviews. 2005; 16: 55-76. Ref.: http://bit.ly/2ROkbS2
  11. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, et al. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther. 2008; 7: 1156-1163. Ref.: http://bit.ly/304lz5Y
  12. Chen W, Bai L, Wang X, Xu S, Belinsky SA, et al. Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol. 2010; 77: 416-423. Ref.: http://bit.ly/2LtjZql
  13. Li Z, Xu X, Bai L, Chen W, Lin Y. Epidermal growth factor receptor-mediated tissue transglutaminase overexpression couples acquired tumor necrosis factor-related apoptosis-inducing ligand resistance and migration through c-FLIP and MMP-9 proteins in lung cancer cells. J Biol Chem. 2011; 286: 21164-21172. Ref.: http://bit.ly/2XhrX84
  14. Danial NN, Korsmeyer SJ. Cell death: critical control points. Cell. 2004; 116: 205-219. Ref.: http://bit.ly/323JoMW
  15. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57-70. Ref.: http://bit.ly/2NskGCE
  16. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell. 2002; 108: 153-164. Ref.: http://bit.ly/2ROrOYM
  17. Fesik SW. Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer. 2005; 5: 876. Ref.: http://bit.ly/326G83F
  18. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat Rev Cancer. 2002; 2: 420-430. Ref.: http://bit.ly/2XK6icY
  19. Falschlehner, C., Emmerich, C.H., Gerlach, B. and Walczak, H., 2007. TRAIL signalling: decisions between life and death. Int J Biochem Cell Biol. 2007; 39: 1462-1475. Ref.: http://bit.ly/2YqbYpC
  20. Ashkenazi A, Dixit VM. Apoptosis control by death and decoy receptors. Curr Opin Cell Biol. 1999; 11: 255-260. http://bit.ly/2FNcIxE
  21. Keogh SA, Walczak H, Bouchier-Hayes L, Martin SJ. Failure of Bcl‐2 to block cytochrome c redistribution during TRAIL‐induced apoptosis. FEBS letters. 2000; 471: 93-98. Ref.: http://bit.ly/2RQt8Kt
  22. Walczak H, Bouchon A, Stahl H, Krammer PH. Tumor necrosis factor-related apoptosis-inducing ligand retains its apoptosis-inducing capacity on Bcl-2-or Bcl-xL-overexpressing chemotherapy-resistant tumor cells. Cancer Res. 2000; 60: 3051-3057. Ref.: http://bit.ly/2FOEr10
  23. Belka C, Schmid B, Marini P, Durand E, Rudner J, et al. Sensitization of resistant lymphoma cells to irradiation-induced apoptosis by the death ligand TRAIL. Oncogene. 2001; 20: 2190-2196. Ref.: http://bit.ly/2RNyFlf
  24. Hinz S, Trauzold A, Boenicke L, Sandberg C, Beckmann S, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD95-and TRAIL-receptor-mediated apoptosis. Oncogene. 2000; 19: 5477-5486. Ref.: http://bit.ly/2XlUvT0
  25. Fulda S, Meyer E, Debatin KM. Inhibition of TRAIL-induced apoptosis by Bcl-2 overexpression. Oncogene. 2002; 21: 2283. Ref.: http://bit.ly/2RNzfiV
  26. Zhang XD, Borrow JM, Zhang XY, Nguyen T, Hersey P. Activation of ERK1/2 protects melanoma cells from TRAIL-induced apoptosis by inhibiting Smac/DIABLO release from mitochondria. Oncogene. 2003; 22: Ref.: http://bit.ly/2RKSbyA
  27. Rudner J, Jendrossek V, Lauber K, Daniel PT, Wesselborg S, et al. Type I and type II reactions in TRAIL-induced apoptosis-results from dose-response studies. Oncogene. 2005; 24: 130-140. Ref.: http://bit.ly/2JjEoLJ
  28. Secchiero P, Zauli G. Tumor necrosis factor-related apoptosis-inducing ligand and the regulation of hematopoiesis. Curr Opin Hematol. 2008; 15: 42-48. Ref.: http://bit.ly/2NsfpuT
  29. Janssen EM, Droin NM, Lemmens EE, Pinkoski MJ, Bensinger SJ, et al. CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death. Nature. 2005; 434: 88. Ref.: http://bit.ly/2xmWsyP
  30. Weckmann M, Collison A, Simpson JL, Kopp MV, Wark PA, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med. 2007; 13: 1308. Ref.: http://bit.ly/2XjAL24
  31. Cretney E, Shanker A, Yagita H, Smyth MJ, Sayers TJ. TNF-related apoptosis-inducing ligand as a therapeutic agent in autoimmunity and cancer. Immunol Cell Biol. 2006; 84: 87. Ref.: http://bit.ly/2FN9kTE
  32. Hilliard B, Wilmen A, Seidel C, Liu TS, Göke R, et al. Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis. J Immunol. 2001; 166: 1314-1319. Ref.: http://bit.ly/2xmWDdt
  33. Lamhamedi-Cherradi SE, Zheng S, Tisch RM, Chen YH. Critical roles of tumor necrosis factor–related apoptosis-inducing ligand in type 1 diabetes. Diabetes. 2003; 52: 2274-2278. Ref.: http://bit.ly/2LxUrIG
  34. Zheng SJ, Wang P, Tsabary G, Chen YH. Critical roles of TRAIL in hepatic cell death and hepatic inflammation. J Clin Invest. 2004; 113: 58-64. Ref.: http://bit.ly/2xoU7nl
  35. Hoffmann O, Priller J, Prozorovski T, Schulze-Topphoff U, Baeva N, et al. TRAIL limits excessive host immune responses in bacterial meningitis. J Clin Invest. 2007; 117: 2004-2013. Ref.: http://bit.ly/2KRyUuP
  36. Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, et al. High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival. Clin Cancer Res. 2003; 9: 762-766. Ref.: http://bit.ly/2KRyUuP
  37. Wright K, Wilson PJ, Kerr J, Do K, Hurst T, et al. Frequent loss of heterozygosity and three critical regions on the short arm of chromosome 8 in ovarian adenocarcinomas. Oncogene. 1998; 17:1185-1188. Ref.: http://bit.ly/2XhEb0H
  38. Pribill I, Speiser P, Leary J, Leodolter S, Hacker NF, et al. High frequency of allelic imbalance at regions of chromosome arm 8p in ovarian carcinoma. Cancer Genet Cytogenet. 2001; 129: 23-29. Ref.: http://bit.ly/2KRHlq3
  39. Pan G, Ni J, Wei YF, Yu G, Gentz R, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science. 1997; 277: 815-818. Ref.: http://bit.ly/2LxWxZ4
  40. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. Cancer Res. 1999; 59: 5683-5686. Ref.: http://bit.ly/2Lr6ZS2
  41. Lee SH, Shin MS, Kim HS, Lee HK, Park WS, et al. Somatic mutations of TRAIL-receptor 1 and TRAIL-receptor 2 genes in non-Hodgkin's lymphoma. Oncogene. 2001; 20: 399-403. Ref.: http://bit.ly/2KWycwq
  42. Fisher MJ, Virmani AK, Wu L, Aplenc R, Harper JC, et al. Nucleotide substitution in the ectodomain of trail receptor DR4 is associated with lung cancer and head and neck cancer. Clin Cancer Res. 2001; 7:1688-1697. Ref.: http://bit.ly/2XHWikq
  43. Shin MS, Kim HS, Lee SH, Park WS, Kim SY, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) and receptor 2 (TRAIL-R2) genes in metastatic breast cancers. Cancer research 2001; 61: 4942-4946. Ref.: http://bit.ly/2XhNSft
  44. Bin L, Thorburn J, Thomas LR, Clark PE, Humphreys R, et al. Tumor-derived mutations in the TRAIL receptor DR5 inhibit TRAIL signaling through the DR4 receptor by competing for ligand binding. J Biol Chem. 2007; 282: 28189-28194. http://bit.ly/2Xi62CJ
  45. MacFarlane M, Kohlhaas SL, Sutcliffe MJ, Dyer MJ, Cohen GM. TRAIL receptor-selective mutants signal to apoptosis via TRAIL-R1 in primary lymphoid malignancies. Cancer Res. 2005; 65: 11265-11270. Ref.: http://bit.ly/305SKWF
  46. van der Sloot AM, Tur V, Szegezdi E, Mullally MM, Cool RH, Samali A, et al. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor. Proc Natl Acad Sci U S A. 2006; 103: 8634-8639. Ref.: http://bit.ly/324Gzvm
  47. Sanlioglu AD, Karacay B, Koksal IT, Griffith TS, Sanlioglu S. DcR2 (TRAIL-R4) siRNA and adenovirus delivery of TRAIL (Ad5hTRAIL) break down in vitro tumorigenic potential of prostate carcinoma cells. Cancer Gene Ther. 2007; 14: 976-984. Ref.: http://bit.ly/2No8hzI
  48. Sanlioglu AD, Korcum AF, Pestereli E, Erdogan G, Karaveli S, et al. TRAIL Death Receptor–4 Expression Positively Correlates With the Tumor Grade in Breast Cancer Patients With Invasive Ductal Carcinoma. Int J Radiat Oncol Biol Phys. 2007; 69: 716-723. Ref.: http://bit.ly/2RU8kC8
  49. Riccioni R, Pasquini L, Mariani G, Saulle E, Rossini A, et al. TRAIL decoy receptors mediate resistance of acute myeloid leukemia cells to TRAIL. Haematologica. 2005; 90: 612-624. Ref.: http://bit.ly/2Xi7yEV
  50. Mérino D, Lalaoui N, Morizot A, Schneider P, Solary E, et al. Differential inhibition of TRAIL-mediated DR5-DISC formation by decoy receptors 1 and 2. Mol Cell Biol. 2006; 26: 7046-7055. Ref.: http://bit.ly/30eCRh1
  51. Emery JG, McDonnell P, Burke MB, Deen KC, Lyn S, et al. Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. 1998; 273: 14363-14367. Ref.: http://bit.ly/2YsMXdl
  52. Devin A, Cook A, Lin Y, Rodriguez Y, Kelliher M, et al. The distinct roles of TRAF2 and RIP in IKK activation by TNF-R1: TRAF2 recruits IKK to TNF-R1 while RIP mediates IKK activation. Immunity. 2000; 12: 419-429. Ref.: http://bit.ly/2XCTJ3e
  53. Yeh WC, Shahinian A, Speiser D, Kraunus J, Billia F, et al. Early lethality, functional NF-κB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 1997; 7: 715-725. Ref.: http://bit.ly/2XoEdbN
  54. Hsu H, Huang J, Shu HB, Baichwal V, Goeddel DV. TNF-dependent recruitment of the protein kinase RIP to the TNF receptor-1 signaling complex. Immunity. 1996; 4:387-396. Ref.: http://bit.ly/2Xhytfg
  55. Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet.1999; 33: 29-55. Ref.: http://bit.ly/2YsNdsP
  56. Peter ME, Krammer PH. The CD95 (APO-1/Fas) DISC and beyond. Cell Death Differ. 2003; 10: 26-35. Ref.: http://bit.ly/2YnfX6p
  57. Song JH, Tse MC, Bellail A, Phuphanich S, Khuri F, et al. Lipid rafts and nonrafts mediate tumor necrosis factor–related apoptosis-inducing ligand–induced apoptotic and nonapoptotic signals in non–small cell Lung Carcinoma Cells. Cancer Res. 2007; 67: 6946-6955. Ref.: http://bit.ly/2J4J35m
  58. Boldin MP, Goncharov TM, Goltsev YV, Wallach D. Involvement of MACH, a novel MORT-IIFADD-interacting protease. Fas/Apo-l. 1996; 803-815.
  59. Chinnaiyan AM1, Tepper CG, Seldin MF, O'Rourke K, Kischkel FC, et al. FADD/MORT1 is a common mediator of CD95 (Fas/APO-1) and tumor necrosis factor receptor-induced apoptosis. J Biol Chem. 1996; 271: 4961-4965. Ref.: http://bit.ly/2NuxCbk
  60. MacFarlane M. TRAIL-induced signalling and apoptosis. Toxicol Lett. 2003; 139: 89-97. Ref.: http://bit.ly/2Jnrmg3
  61. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, et al. The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain. Immunity. 1997; 7: 813-820. Ref.: http://bit.ly/2LFh2mL
  62. Li H, Lin X. Positive and negative signaling components involved in TNFα-induced NF-κB activation. Cytokine. 2008; 41: 1-8. Ref.: http://bit.ly/308Su9l
  63. Trauzold A, Siegmund D, Schniewind B, Sipos B, Egberts J, et al. TRAIL promotes metastasis of human pancreatic ductal adenocarcinoma. Oncogene. 2006; 25: 7434. Ref.: http://bit.ly/2KSnGq4
  64. Ricci MS, Kim SH, Ogi K, Plastaras JP, Ling J, et al. Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell. 2007; 12: 66-80. Ref.: http://bit.ly/2J5frEL
  65. Secchiero P, Gonelli A, Carnevale E, Milani D, Pandolfi A, et al. TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways. Circulation. 2003; 107: 2250-2256. Ref.: http://bit.ly/2LyCkSD


Figure 1

Figure 1

Similar Articles

Recently Viewed

Read More

Most Viewed

Read More

Help ?